Instrument Inactif

Autres langues Viskase Companies, Inc. Other OTC

Actions

VKSC

US92831R2013

Conteneurs et emballages hors papier

Autres langues

03/08	Viskase Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/05	Viskase Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
01/05	Viskase Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
01/05	Viskase Companies, Inc. Auditor Raises 'Going Concern' Doubt
21/04	Viskase Companies, LLC Amends Credit Agreement and Extends Maturity Date
16/04	Enzon Pharmaceuticals, Inc has Changed its Name to Viskase Holdings, Inc
15/04	Viskase Holdings, Inc. Announces Chief Financial Officer Changes, Effective on April 10, 2026
15/04	Viskase Holdings, Inc. Appoints Joseph D. King as Executive Vice President ,Effective on April 10, 2026
26/03	Viskase Holdings, Inc. Announces Departure of Richard L. Feinstein as Chief Financial Officer, Effective March 26, 2026
26/03	Viskase Holdings, Inc. Announces CEO Changes, Effective March 26, 2026
26/03	Viskase Holdings, Inc. Announces Board and Committee Changes Following Merger, Effective March 26, 2026
26/03	Viskase Companies, Inc. completed the acquisition of Enzon Pharmaceuticals, Inc. from a group of shareholders for $7.8 million in a reverse merger transaction.
25/03	Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
24/03	Enzon Announces Reverse Stock Split
19/03	Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
16/03	Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
11/03	Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
09/03	Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
02/03	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
27/02	Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
30/01	Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
12/11	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
24/10/25	Enzon and Viskase announce amendment to merger agreement
24/10/25	Enzon and Viskase Announce Amendment to Merger Agreement
14/08/25	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025